MarketCap
Facebook
X
TelegramAnnual report 2026
added 03-03-2026
STAAR Surgical Company Accounts Receivables 2011-2026 | STAA
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables STAAR Surgical Company
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.1 M | 77.9 M | 94.7 M | 62.4 M | 43.5 M | 31 M | - | 25.9 M | 17.9 M | 16.3 M | 11.1 M | 10.7 M | - | 8.54 M | 9.09 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 94.7 M | 8.54 M | 35.3 M |
Quarterly Accounts Receivables STAAR Surgical Company
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60.1 M | 34.4 M | 39.9 M | 77.9 M | 105 M | 93.8 M | 64.6 M | 94.7 M | 112 M | 94.4 M | 63.5 M | 62.4 M | 55.4 M | 62.8 M | 47.1 M | 43.5 M | 41.9 M | 48.6 M | 33.7 M | 31 M | 42.1 M | 39.5 M | 34.5 M | - | 30.8 M | 33 M | 26.6 M | 25.9 M | 25.9 M | 25.9 M | 25.9 M | 17.9 M | 20 M | 20 M | 20 M | 15.7 M | 16.3 M | 16.3 M | 16.3 M | 11.1 M | 12.8 M | 12.5 M | 11 M | 10.7 M | 11.7 M | 12.7 M | 11.1 M | - | 9.47 M | 10.3 M | 8.61 M | 8.54 M | 8.54 M | 8.54 M | 8.54 M | 9.09 M | 9.09 M | 9.09 M | 9.09 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 112 M | 8.54 M | 33.5 M |
Accounts Receivables of other stocks in the Medical instruments industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
1.7 B | $ 16.47 | -1.08 % | $ 8.45 B |  USA |
 |
Atrion Corporation
ATRI
|
23 K | - | - | $ 810 M | USA |
 |
The Cooper Companies
COO
|
829 M | $ 69.5 | -1.13 % | $ 13.8 B | USA |
 |
electroCore
ECOR
|
1.03 M | $ 7.04 | - | $ 59.7 K | USA |
 |
Ekso Bionics Holdings
EKSO
|
7.31 M | $ 9.6 | -1.54 % | $ 23.3 M | USA |
 |
BioLife Solutions
BLFS
|
9.17 M | $ 19.0 | -1.4 % | $ 875 M | USA |
 |
AtriCure
ATRC
|
66.7 M | $ 28.76 | -1.47 % | $ 1.37 B | USA |
 |
Glaukos Corporation
GKOS
|
39.8 M | $ 115.08 | -1.41 % | $ 5.57 B | USA |
 |
Haemonetics Corporation
HAE
|
203 M | $ 58.1 | -0.54 % | $ 2.92 B | USA |
 |
Harvard Bioscience
HBIO
|
16 M | $ 5.53 | - | $ 245 M | USA |
 |
iRhythm Technologies
IRTC
|
75.7 M | $ 115.36 | -1.59 % | $ 3.69 B | USA |
 |
Repro Med Systems
KRMD
|
6.21 M | $ 4.25 | -0.23 % | $ 196 M | USA |
 |
Masimo Corporation
MASI
|
141 M | $ 178.34 | -0.08 % | $ 9.51 B | USA |
 |
Microbot Medical
MBOT
|
159 K | $ 2.32 | -1.91 % | $ 106 M |  Israel |
 |
Milestone Scientific
MLSS
|
313 K | $ 0.29 | - | $ 23.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
430 M | $ 25.51 | -1.22 % | $ 4.29 B | USA |
 |
Pro-Dex
PDEX
|
16.4 M | $ 48.53 | - | $ 160 M | USA |
 |
ICU Medical
ICUI
|
181 M | $ 121.67 | -1.08 % | $ 3 B | USA |
 |
ResMed
RMD
|
576 M | $ 224.04 | -0.34 % | $ 32.7 B | USA |
 |
InfuSystem Holdings
INFU
|
16.9 M | $ 9.43 | - | $ 195 M | USA |
 |
Retractable Technologies
RVP
|
7.9 M | $ 0.71 | -0.07 % | $ 21.3 M | USA |
 |
Isoray
ISR
|
6 K | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
1.53 B | $ 449.17 | -0.75 % | $ 160 B | USA |
 |
Stereotaxis
STXS
|
5.85 M | $ 1.85 | -1.86 % | $ 168 M | USA |
 |
LeMaitre Vascular
LMAT
|
33.6 M | $ 109.83 | 0.61 % | $ 2.49 B | USA |
 |
Teleflex Incorporated
TFX
|
346 M | $ 114.86 | -0.2 % | $ 5.13 B | USA |
 |
Merit Medical Systems
MMSI
|
204 M | $ 66.72 | -1.61 % | $ 3.95 B | USA |
 |
Utah Medical Products
UTMD
|
3.52 M | $ 63.75 | 1.3 % | $ 207 M | USA |
 |
Predictive Oncology
POAI
|
32.1 K | - | - | $ 31.1 M | USA |
 |
Pulse Biosciences
PLSE
|
274 K | $ 21.68 | -5.49 % | $ 1.46 B | USA |
 |
West Pharmaceutical Services
WST
|
574 M | $ 258.0 | 0.4 % | $ 18.7 B | USA |
 |
NeuroMetrix
NURO
|
193 K | - | 5.05 % | $ 9.02 M | USA |
 |
STERIS plc
STE
|
1.04 B | $ 219.18 | -0.37 % | $ 21.6 B | USA |
 |
AngioDynamics
ANGO
|
42.9 M | $ 9.51 | -3.35 % | $ 389 M | USA |
 |
Becton, Dickinson and Company
BDX
|
2.99 B | $ 154.32 | -0.59 % | $ 44.4 B | USA |
 |
Nephros
NEPH
|
1.5 M | $ 2.81 | -1.75 % | $ 29.2 M | USA |
 |
OraSure Technologies
OSUR
|
22.2 M | $ 3.05 | -1.14 % | $ 224 M | USA |
 |
Repligen Corporation
RGEN
|
124 M | $ 116.46 | -0.42 % | $ 6.49 M | USA |